Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesEffects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Annals of Rheumatic Diseases, 09/08/09
Dore RK et al. – Denosumab increases BMD and reduces bone turnover in patients with RA and may provide a new therapeutic option for reducing systemic bone loss in patients with RA.
Methods- Randomized, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor, in patients with RA concurrently receiving treatment with bisphosphonates or glucocorticoids
- Patients received subcutaneous placebo (n=75), denosumab (60 mg; n=71), or denosumab (180 mg; n=72) at baseline and 6 months
- Denosumab treatment increased mean lumbar spine and hip BMD and reduced sCTx-I and P1NP versus placebo through 12 months, regardless of baseline BMD or marker levels or concomitant bisphosphonate or glucocorticoid use
Related Articles
Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The Journal of Urology, 11/16/09
Relevance Score: 87%
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Relevance Score: 83%
Bone health and prostate cancer
Prostate Cancer & Prostatic Diseases, 11/13/09
Relevance Score: 77%
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
The Role of Quantitative Bone Scanning in the Assessment of Bone Turnover in Patients with Charcot Foot
Diabetes Care, 11/25/09
Assessment of Regional Changes in Skeletal Metabolism Following 3 and 18 Months of Teriparatide Treatment
Journal of Bone and Mineral Research, 11/25/09
Relationship Between Genotype and Skeletal Phenotype in Children and Adolescents With Osteogenesis Imperfecta
Journal of Bone and Mineral Research, 11/25/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
Annals of Rheumatic Diseases, 11/24/09
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis
Annals of Rheumatic Diseases, 11/23/09
Sponsor
Article Search
Sponsor